Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | AHCY | P23526 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28313164 | 0.88 | AHCY (0.45) | GSK3BADORA2AADORA1AHCYALDH1A1 | |
| SCHEMBL14125909 | 0.83 | ADORA2A (0.51) | GSK3BADORA2AADORA1AHCYALDH1A1 | |
| SCHEMBL28406876 | 0.82 | ADORA2A (0.50) | GSK3BADORA2AADORA1AHCYALDH1A1 | |
| SCHEMBL28113155 | 0.82 | GSK3B (0.51) | GSK3BADORA2AADORA1AHCYALDH1A1 | |
| SCHEMBL28086747 | 0.79 | ADORA2A (0.48) | GSK3BADORA2AADORA1AHCYALDH1A1 | |
| SCHEMBL1272854 | 0.78 | ADORA2A (0.51) | GSK3BADORA2AADORA1AHCYPI4KA | |
| SCHEMBL28145519 | 0.77 | ADORA2A (0.50) | GSK3BADORA2AADORA1AHCYALDH1A1 | |
| SCHEMBL28406873 | 0.77 | ADORA2A (0.50) | GSK3BADORA2AADORA1AHCYALDH1A1 | |
| SCHEMBL385843 | 0.77 | ADORA2A (0.55) | GSK3BADORA2AADORA1AHCYADORA3 | |
| Sulfuric Acid SCHEMBL10790466 | 0.76 | GSK3B (0.46) | GSK3BADORA2AADORA1ALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106536532-B | Tenofovir prodrug novel polymorphic and its preparation method and application | 江苏豪森药业集团有限公司 | 2019-09-03 | — | — | CN | claimed |
| CN-110146639-A | A kind of analysis method of the novel nucleoside acids reverse transcriptase inhibitor in relation to substance | 南京正大天晴制药有限公司 | 2019-08-20 | — | — | CN | claimed |
| CN-106536532-A | New polycrystalline form of tenofovir prodrug, and preparation method and application therefor | 江苏豪森药业集团有限公司 | 2017-03-22 | — | — | CN | claimed |
| CN-105399771-A | Crystal form of tenofovir prodrug, preparation method and application of crystal form | JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL CO LTD | 2016-03-16 | — | — | CN | claimed |
| CN-101193642-A | Nucleotide analog prodrug and preparation thereof | BORUI BIOLOG MEDICAL TECHNOLOG (CN) | 2008-06-04 | — | — | CN | claimed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| CN-117624242-A | Purification method of tenofovir alafenamide intermediate | 上海迪赛诺化学制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117510542-A | Ai Miti norfovir fumarate spherical crystal and preparation method thereof | 天津大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-114591367-B | Continuous production method of tenofovir disoproxil fumarate | 安徽贝克制药股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-113583050-B | Tenofovir Wei Linsuan ester a crystal form and preparation and application thereof | 西安新通药物研究股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-113583048-B | Tenofovir Wei Linsuan ester c crystal form and preparation and application thereof | 西安新通药物研究股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-113583049-B | Tenofovir Wei Linsuan ester e crystal form and preparation and application thereof | 西安新通药物研究股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-103211826-A | Antiviral pharmaceutical composition as well as preparation method and application thereof | FUJIAN COSUNTER PHARMACEUTICAL CO LTD | 2013-07-24 | — | — | CN | disclosed |
| CN-102670629-A | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES INC | 2012-09-19 | — | — | CN | disclosed |
| CN-1738628-B | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES INC | 2012-06-06 | — | — | CN | disclosed |
| CN-101878032-A | Potent combination of zidovudine and agents selected against the K65R mutation in HIV polymerase | RFS PHARMA LLC | 2010-11-03 | — | — | CN | disclosed |
| CN-101574356-A | Tenofovir disoproxil pharmaceutical salt and preparations thereof | HEILONGJIANG CALIFORNIA INTERN (CN) | 2009-11-11 | — | — | CN | disclosed |
| CN-101066981-A | Non-cyclic nucleoside phosphonate compound and its composition, prepn process and use | SHANGHAI INST OF MEDICINES CAS (CN) | 2007-11-07 | — | — | CN | disclosed |
| CN-1938017-A | Therapeutic combinations | AGOURON PHARMA (US) | 2007-03-28 | — | — | CN | disclosed |
| CN-1738628-A | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES INC (US) | 2006-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | GSK3B 755/4885ADORA2A 112/4885ADORA1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.